NRX Pharmaceuticals (NRXP) Payables (2017 - 2026)

NRX Pharmaceuticals (NRXP) has 10 years of Payables data on file, last reported at $13.2 million in Q1 2026.

• On a quarterly basis, Payables fell 7.05% year-over-year to $13.2 million in Q1 2026; TTM through Mar 2026 was $13.2 million, a 7.05% decrease from a year earlier, with the FY2025 full-year figure at $16.6 million, up 69.66% from the prior year.
• Payables for Q1 2026 stood at $13.2 million, down from $16.6 million in the prior quarter.
• Over the last five years, Payables for NRXP reached as high as $16.6 million in Q4 2025 and fell as low as $2.1 million in Q4 2022.
• Historically, Payables has averaged $8.7 million across 5 years, with a median of $6.8 million in 2024.
• Across the five-year window, Payables slumped 89.36% in 2022 and soared 516.01% in 2023, its largest moves.
• Year by year, Payables stood at $2.1 million in 2022, then soared by 120.02% to $4.6 million in 2023, then jumped by 110.13% to $9.8 million in 2024, then surged by 69.66% to $16.6 million in 2025, then decreased by 20.57% to $13.2 million in 2026.
• Per Business Quant data, the three most recent Payables figures were $13.2 million in Q1 2026, $16.6 million in Q4 2025, and $14.2 million in Q3 2025.